Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 10/20 | 1.00 |
| ▸ | RAB9A | P51151 | 7/20 | 1.00 |
| ▸ | MAPT | P10636 | 6/20 | 1.00 |
| ▸ | NPC1 | O15118 | 6/20 | 1.00 |
| ▸ | POLB | P06746 | 2/20 | 1.00 |
| ▸ | HMGB1 | P09429 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 8/20 | 0.84 |
| ▸ | TP53 | P04637 | 3/20 | 0.84 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.84 |
| ▸ | PPARG | P37231 | 4/20 | 0.77 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.77 |
| ▸ | XDH | P47989 | 2/20 | 0.72 |
| ▸ | MIF | P14174 | 1/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.71 |
| ▸ | HPGD | P15428 | 7/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.71 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.71 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.71 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Calycosin SCHEMBL30335127 | 1.00 | KDM4E (1.00) | KDM4ERAB9AMAPTNPC1POLB | |
| Cladrin SCHEMBL738092 | 0.91 | KDM4E (1.00) | KDM4ERAB9AMAPTNPC1POLB | |
| SCHEMBL2069826 | 0.90 | KDM4E (0.84) | KDM4ERAB9AMAPTNPC1POLB | |
| SCHEMBL29788255 | 0.90 | KDM4E (0.84) | KDM4ERAB9AMAPTNPC1POLB | |
| SCHEMBL10441842 | 0.89 | KDM4E (0.80) | KDM4ERAB9AMAPTNPC1POLB | |
| Glycitein SCHEMBL5483545 | 0.88 | HDAC6 (0.91) | KDM4ERAB9AMAPTNPC1POLB | |
| SCHEMBL28124530 | 0.88 | KDM4E (0.80) | KDM4ERAB9AMAPTNPC1POLB | |
| Odoratin SCHEMBL1248967 | 0.87 | PTPN1 (1.00) | KDM4ERAB9AMAPTNPC1POLB | |
| SCHEMBL29929620 | 0.87 | KDM4E (0.77) | KDM4ERAB9AMAPTNPC1POLB | |
| SCHEMBL2491956 | 0.86 | MAPT (0.76) | KDM4ERAB9AMAPTNPC1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1446 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122084809-A | Feature map detection method of detumescence particles or intermediate extract thereof and application thereof | — | 2026-05-26 | — | — | CN | claimed |
| CN-117327135-B | Method for increasing leaching of saccharides and glycoside components and application thereof | INSTITUTE OF CHINESE MATERIA MEDICA, CHINA ACADEMY OF CHINESE MEDICAL SCIENCES (CN) | 2026-05-26 | — | — | CN | claimed |
| CN-120939042-B | Application of cajanin, cordyceps polysaccharide or calycosin in combination in preparation of medicine for relieving toxic injury of vomitoxin | 吉林大学 | 2026-05-19 | — | — | CN | claimed |
| CN-122031494-A | Application of calycosin glycoside in preparation of medicines for relieving ulcerative colitis | 黄冈师范学院 | 2026-05-15 | — | — | CN | claimed |
| CN-119732967-B | Application of astragalus-curcuma zedoary medicine pair active ingredient composition in preparation of anti-tumor metastasis medicines | 中国药科大学 | 2026-05-15 | — | — | CN | claimed |
| CN-122031598-A | Preparation method and application of nephritis medicine | 五源本草(山东)健康科技有限公司 | 2026-05-15 | — | — | CN | claimed |
| CN-122005706-A | Qishenpngji granule for treating ventricular premature beat and quality detection method thereof | 江苏省中医院 | 2026-05-12 | — | — | CN | claimed |
| CN-121577776-A | Fingerprint analysis method of seven-ingredient radix stephaniae tetrandrae and astragalus membranaceus particles | 正大青春宝药业有限公司 | 2026-02-27 | — | — | CN | claimed |
| EP-3888670-B1 | DRUG FOR TREATING LEUKOPENIA, PREPARATION METHOD THEREFOR AND USE THEREOF | MONYAN PHARMACEUTICAL CO LTD (CN) | 2025-12-24 | — | — | EP | claimed |
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | claimed |
| CN-112641916-B | Traditional Chinese medicine ointment formula for building body and preparation method thereof | 辽宁上药好护士药业（集团）有限公司 | 2022-02-01 | — | — | CN | claimed |
| CN-113960184-A | Establishment and quality detection method of blood-replenishing and motherwort-tonifying pill fingerprint spectrum | 株洲千金药业股份有限公司 | 2022-01-21 | — | — | CN | claimed |
| US-10406191-B2 | Compounds, extracts and methods from chinese medicinal herb sophora flavescens that inhibit airway contraction | Li, Xui-Min (US) | 2019-09-10 | — | — | US | claimed |
| US-20150359834-A1 | COMPOUNDS, EXTRACTS AND METHODS FROM CHINESE MEDICINAL HERB SOPHORA FLAVESCENS THAT INHIBIT AIRWAY CONTRACTION | LI, XIU-MIN | 2015-12-17 | — | — | US | claimed |
| WO-2014113784-A1 | COMPOUNDS, EXTRACTS AND METHODS FROM CHINESE MEDICINAL HERB SOPHORA FLAVESCENS THAT INHIBIT AIRWAY CONTRACTION | LI XIU-MIN (US) | 2014-07-24 | — | — | WO | claimed |
| CN-102657641-A | Application of calycosin to preparation of medicine for resisting vascular dementia | UNIV XINXIANG MEDICAL | 2012-09-12 | — | — | CN | claimed |
| US-20120016019-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING CANCER | LEE GEE-HWOON (KR) | 2012-01-19 | — | — | US | claimed |
| US-20120016017-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING CANCER | LEE GEE-HWOON (KR) | 2012-01-19 | — | — | US | claimed |
| US-20120015056-A1 | COMPOSITION COMPRISING EXTRACTS OR FRACTIONS OF SPECIFIC PLANTS, USE THEREOF AND PROCESS FOR PREPARING THE EXTRACTS | LEE GEE-HWOON (KR) | 2012-01-19 | — | — | US | claimed |
| WO-2012008762-A2 | COMPOSITION COMPRISING EXTRACTS OR FRACTIONS OF SPECIFIC PLANTS, USE THEREOF AND PROCESS FOR PREPARING THE EXTRACTS | LEE GEE-HWOON (KR) | 2012-01-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120016019-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING CANCER | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, H1-5, KRAS | KDM4E 4070/4885RAB9A 755/4885MAPT 3047/4885 |
| US-20120016017-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING CANCER | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, WASHC5, ASAH1 | KDM4E 3250/4885RAB9A 663/4885MAPT 3541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.